| MBRX - Moleculin Biotech Inc (Healthcare: Biotechnology) | Projected Earnings Date: 0000-02-29 (Delayed quote data 2026-02-10) |
|
|
|||||||||||||||||
|
|
|
| Company Profile | |
| Moleculin Biotech Inc is a clinical-stage pharmaceutical company with its focus on the treatment of highly resistant cancers and viruses through the development of its drug candidates. The company has three core technologies: Annamycin which is a next generation anthracycline; Immune/Transcription Modulators, of which WP1066 is a member; and Metabolism/Glycosylation Inhibitors, of which WP1122 is a member. | |
| Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. |